Medifoxamine has been found to act preferentially as a relatively weak [[dopamine reuptake inhibitor]],<ref name="pmid8039537" /><ref name="SalehTurner1992">{{cite journal|last1=Saleh|first1=S|last2=Turner|first2=P|title=Ocular hypotensive effects of medifoxamine.|journal=British Journal of Clinical Pharmacology|volume=34|issue=3|year=1992|pages=269–271|issn=0306-5251|doi=10.1111/j.1365-2125.1992.tb04136.x}}</ref><ref name="VaugeoisPouhé1994">{{cite journal|last1=Vaugeois|first1=J.-M.|last2=Pouhé|first2=D.|last3=Lemonnier|first3=F.|last4=Costentin|first4=J.|title=Neurochemical and behavioral evidence for a central indirect dopaminergic agonist activity of the antidepressant medifoxamine in mice|journal=European Neuropsychopharmacology|volume=4|issue=3|year=1994|pages=323–324|issn=0924-977X|doi=10.1016/0924-977X(94)90140-6}}</ref><ref name="Berk2000">{{cite journal|last1=Berk|first1=Michael|title=Depression therapy: Future prospects|journal=International Journal of Psychiatry in Clinical Practice|volume=4|issue=4|year=2000|pages=281–286|issn=1365-1501|doi=10.1080/13651500050517830}}</ref> but also as an even weaker [[serotonin reuptake inhibitor]] ([[IC50|IC<sub>50</sub>]] = 1,500&nbsp;nM)<ref name="pmid8039537" /> and as a weak [[receptor antagonist|antagonist]] of the [[5-HT2A receptor|5-HT<sub>2A</sub>]] and [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]]s (IC<sub>50</sub> = 950 and 980, respectively; notably greater [[affinity (pharmacology)|affinity]] relative to [[amitriptyline]] and [[imipramine]]).<ref name="pmid8039537" /><ref name="pmid7988407">{{cite journal | vauthors = Martin P, Lemonnier F | title = [The role of type 2 serotonin receptors, 5-HT2A and 5-HT2C, in depressive disorders: effect of medifoxamine] | language = French | journal = Encephale | volume = 20 | issue = 4 | pages = 427–35 | year = 1994 | pmid = 7988407 | doi = | url = }}</ref><ref name="pmid8275921">{{cite journal | vauthors = Olié JP, Galinowski A, Lehert P, Lemonnier F, Lôo H | title = [Randomized double-blind comparative study of the efficacy and tolerance of medifoxamine and imipramine in depressed patients] | language = French | journal = Encephale | volume = 19 | issue = 4 | pages = 333–40 | year = 1993 | pmid = 8275921 | doi = | url = }}</ref> It is known to produce two [[active metabolite]]s during [[first-pass metabolism]] in the [[liver]], [[CRE-10086]] (N-methyl-2,2-diphenoxyethylamine) and [[CRE-10357]] (N,N-dimethyl-2-hydroxyphenoxy-2-phenoxyethylamine).<ref name="pmid8039537" /> The IC<sub>50</sub> values of CRE-10086 for [[serotonin transporter]], 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> binding are 450&nbsp;nM, 330&nbsp;nM, and 700&nbsp;nM, respectively, while those of CRE-10357 are 660&nbsp;nM, 1,600&nbsp;nM, and 6,300 &nbsp;M.<ref name="pmid8039537" /> Medifoxamine and its metabolites lack affinity for other [[serotonin receptor]]s including [[5-HT1A receptor|5-HT<sub>1A</sub>]], [[5-HT1B receptor|5-HT<sub>1B</sub>]], [[5-HT1D receptor|5-HT<sub>1D</sub>]], and [[5-HT3 receptor|5-HT<sub>3</sub>]] (>10,000&nbsp;nM).<ref name="pmid8039537" /> As medifoxamine is metabolized extensively in the liver during first-pass metabolism, and as these metabolites have as much as 3-fold greater activity relative to medifoxamine, it is likely that they contribute significantly to the [[pharmacology]] of the parent drug.<ref name="pmid8039537" />

 
Unlike many [[tricyclic antidepressant]]s, medifoxamine lacks [[anticholinergic]] and [[alpha blocker]] properties (very low affinity for the [[muscarinic acetylcholine receptor]]s and 10-fold lower affinity for the [[α1-adrenergic receptor|α<sub>1</sub>-adrenergic receptor]] relative to 5-HT<sub>2</sub> binding sites),<ref name="pmid8039537" /><ref name="SalehTurner1992" /><ref name="RandhawaHedges1988">{{cite journal|last1=Randhawa|first1=M. A.|last2=Hedges|first2=A.|last3=Johnston|first3=A.|last4=Turner|first4=P.|title=A psychopharmacological study to assess anti-muscarinic and central nervous effects of medifoxamine in normal volunteers|journal=Human Psychopharmacology: Clinical and Experimental|volume=3|issue=3|year=1988|pages=195–200|issn=0885-6222|doi=10.1002/hup.470030307}}</ref> and is also apparently inactive as a [[norepinephrine reuptake inhibitor]] (although the same source stating this also states that it is inactive as a serotonin reuptake inhibitor, which was subsequently found not to be the case).<ref>{{cite book|title=ANNUAL REPORTS IN MED CHEMISTRY V20 PPR|url=https://books.google.com/books?id=j-3Cd_SWIksC&pg=PA35|date=11 September 1985|publisher=Academic Press|isbn=978-0-08-058364-8|pages=35–}}</ref> Studies in mice revealed that the drug does not possess any [[sedative]] or [[stimulant|locomotor stimulant]] effects.<ref name="pmid8039537" /> In accordance with all of the preceding, medifoxamine was found to be [[drug tolerability|well-tolerated]] at dosages of 100–300&nbsp;mg per day in [[clinical trial]]s.<ref name="pmid8039537" /> [[Double-blind]] [[controlled study|controlled]] [[Clinical trial|clinical studies]] have found it to have similar effectiveness to imipramine, [[clomipramine]], and [[maprotiline]] in the treatment of [[depression (mood)|depression]].<ref name="pmid8039537" /><ref name="pmid8668756" /><ref name="pmid8275921" /><ref name="RandhawaHedges1988" />
